# Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion

> **NCT00160199** · PHASE4 · COMPLETED · sponsor: **Solvay Pharmaceuticals** · enrollment: 240 (actual)

## Conditions studied

- Secondary Amenorrhea

## Interventions

- **DRUG:** PROMETRIUM® 300 mg
- **DRUG:** PROMETRIUM® 400 mg

## Key facts

- **NCT ID:** NCT00160199
- **Lead sponsor:** Solvay Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2010-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00160199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00160199, "Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00160199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*